By detecting as little as one parasite per microliter of whole blood, the test could be used to further future efforts aimed at malaria eradication.
The results affirmed the company's preliminary earnings issued last month.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
The technology, called LAMP, produces DNA at a single temperature and at higher amounts than can be achieved with PCR-based amplification.
Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.
The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.
The life science and diagnostics company's revenues were short of analyst expectations, though its earnings per share were in line with estimates.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.